{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_17380", "batch_size": 260, "batch_pos": 235, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 2, "answer": "no", "rationale": "This is a factual report of deal details ('secures... doses', 'includes an option').", "method": "llm_batch", "batch_id": "batch_2_11108", "batch_size": 260, "batch_pos": 213, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 3, "answer": "no", "rationale": "The segment describes a deal for vaccine supply. Scale is about doses, not the realised impact of the threat.", "method": "llm_batch", "batch_id": "batch_3_2112", "batch_size": 260, "batch_pos": 166, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 4, "answer": "no", "rationale": "No loaded rhetorical question present.", "method": "llm_batch", "batch_id": "batch_4_13728", "batch_size": 260, "batch_pos": 159, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 5, "answer": "no", "rationale": "Reports details of the deal, lacking explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_14776", "batch_size": 260, "batch_pos": 157, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser used in conjunction with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_18424", "batch_size": 260, "batch_pos": 137, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_8916", "batch_size": 260, "batch_pos": 119, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 8, "answer": "yes", "rationale": "Describes the terms of a deal ('secures up to 665,000 doses', 'includes an option for a further 40 million').", "method": "llm_batch", "batch_id": "batch_8_18056", "batch_size": 260, "batch_pos": 256, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
